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Abstract. Next-generation sequencing (NGS) has generated 
a large amount of sequence data with the requirement of 
frequent critical revisions of reported mutations. This innova-
tive tool has proved to be effective in detecting pathogenic 
mutations; however, it requires a certain degree of experience 
to identify incidental findings. In the present study, whole 
exome sequencing analysis was performed for the molecular 
diagnosis and correct genotype/phenotype correlation between 
parents and a patient presenting with an atypical phenotype. In 
addition, mevalonic acid quantification and frequency analysis 
of detected variants in public databases and X-chromosome 
inactivation (XCI) studies on the patient's mother were 
performed. V377I as well as the S135L mutations were identi-
fied on the mevalonate kinase deficiency gene and the levels 
of mevalonic acid in the patient were 5,496 µg/ml. A D59G 
variation, reported in ESP6500 in two healthy individuals, 
was found on the Martin Probst syndrome gene (RAB40AL). 
Based on XCI studies on the patient's mother, it is likely 
that RAB40AL escapes XCI, while still remaining balanced. 
In conclusion, the results of the present study indicated that 
the Martin Probst syndrome is an X‑linked condition, which 
is probably not caused by RAB40AL mutations. Although 
NGS is a powerful tool to identify pathogenic mutations, the 
analysis of genetic data requires expert critical revision of all 
detected variants.
Introduction
Next-generation sequencing (NGS) has introduced a 
novel era, in which it has become possible to rapidly and 
cost-efficiently obtain large amounts of sequence data for 
patients. NGS analysis is therefore currently regarded as a 
first-choice diagnostic tool, particularly in cases in which 
phenotypical and clinical features are unclear or atypical, 
leaving Sanger sequencing for the confirmation of detected 
variants (1). The correct placement of a preliminary clinical 
diagnosis and subsequent selection of candidate genes for 
molecular analysis are challenging when patients present 
with signs and symptoms that do not match any known clin-
ical condition. In these cases, the use of Sanger sequencing 
to produce a molecular diagnosis is unreasonable due to the 
high cost and effort required.
In these cases, whole exome sequencing (WES) can be 
an appropriate tool to detect pathogenic mutations; however, 
this requires an effective strategy for filtering results and 
in‑depth analysis to meaningfully interpret incidental find-
ings (2,3). Furthermore, in silico and functional studies may 
be necessary to attribute the correct value to unexpected 
results. 
The present study reports on a patient who was selected, 
given the clinical phenotype complexity, for proband-parents 
(trios) analysis using WES with the aim of detecting all the 
possible genetic variants that may have generated the patient's 
phenotype.
The present study confirmed that it is essential to filter 
and confirm each step of the NGS based on the decision of a 
team that has the necessary expertise to assess the impact of 
the detected variants.
Materials and methods
Ethical approval. The technical and scientific review board of 
the Institute for Maternal and Child Health, Istituto di Ricovero 
e Cura a Carattere Scientifico (IRCCS) ‘Burlo Garofolo’ 
(Trieste, Italy) (no. 185/08, 19/08/2008) approved the present 
study. For enrolment of the child and the parents in the present 
study, informed consent was obtained from the parents.
Patient. A six-year-old boy with non-consanguineous parents 
was admitted to the Paediatric Department of the IRCCS 
‘Burlo Garofolo’ (Trieste, Italy) due to neurogenic diabetes 
insipidus, mild hepatomegaly and recurrent episodes of fever 
with skin rash and cervical adenitis. 
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DNA extraction. Genomic DNA (gDNA) was extracted from 
1-2 ml EDTA-anticoagulated blood obtained from the proband 
and his parents using an EZ1 DNA Blood kit (Qiagen, Hilden, 
Germany) according to manufacturer's instructions.
WES analysis. A total of 3 µg gDNA was used for library prepa-
ration using TruSeq™ Exome Enrichment 62 Mb kit (Illumina 
Inc., San Diego, CA, USA). A paired-end sequencing of each 
library was performed on an Illumina HiSeq1000 (Illumina 
Inc.). Raw sequencing data were collected as unmapped 
100‑bp reads in fastQ format. CLC Genomics Workbench 
version 6.5 software (CLC Bio; Qiagen) was employed to check 
the quality of the reads, to map reads back to the human refer-
ence genome, version hg19, to calculate the overall coverage, 
to perform local re-alignment and base quality re-calibration 
and, finally, to call single nucleotide variants (SNVs) and small 
insertion/deletions (INDELs). All of these data were collected 
into a standardized variant call format, version 4.1 (4). 
SNVs/INDELs were annotated using ANNOVAR soft-
ware (ht tp://www.openbioinformatics.org/annovar/; 
version 2013Aug23) referring to several public databases, 
including National Center of Biotechnology Information 
dbSNP build138 (http://www.ncbi.nlm.nih.gov/SNP/), the 
1000 Genomes Project (http://www.1000genomes.org/) and the 
National Heart, Lung, and Blood Institute Exome Sequencing 
Project Exome Variant Server (http://evs.gs.washington.
edu/EVS/) (5).
Bioinformatic and statistical analyses. SNVs/INDELs were 
first analyzed with the aim of evaluating all known mutations 
already associated with the clinical manifestations of the 
patient. Subsequently, SNVs/INDELs were filtered with the 
purpose of selecting variants which are poorly represented 
within the general population and potentially ‘pathogenic’; 
to this end, variants were selected according to the following 
inclusion criteria: A) Minor allelic frequency <0.03 in residents 
with ancestry from northern and western Europe, referring 
to the 1000 Genomes Project (http://www.1000genomes.rg/) 
and NHLBI Exome Sequencing Project (ESP) Exome Variant 
Server (http://evs.gs.washington.du/EVS/); B) homozygous 
variants carried by the proband; and C) variants predicted as 
‘pathogenic’ based on Polyphen-2 (6), Mutation Taster and 
LRT scores, as recorded in dbNSFP v2.0 (7,8).
Polymerase chain reaction (PCR) and Sanger analyses. PCR 
amplification was performed for the specific gene-coding 
sequences of the MVK and RAB40AL genes. 50 ng DNA was 
amplified using KAPA 2G Fast Hot Start Readymix (initial 
concentration, 2X; final concentration, 1X; respective primer 
initial concentration, 10 µM; final concentration, 0.2 µM; final 
volume, 25 µl) (Resnova, Roma, Italy) and a 2720 Thermal 
Cycler (Applied Biosystems, Thermo Fisher Scientific, 
Waltham, MA, USA). Amplification products were purified 
with ExoSAP-IT enzyme (Affymetrix, Inc., Santa Clara, CA, 
USA) at 37˚C for 20 sec, subsequently inactivated at 85˚C for 
10 sec, and directly sequenced by the Sanger method using 
ABI Prism 3.1 Big Dye terminator chemistry (Invitrogen Life 
Technologies, Carlsbad, CA, USA) and BigDye XTerminator 
Purification kit (Applied Biosystems). Runs were performed on 
the ABI Prism 3130XL automated DNA sequencer (Applied 
Biosystems). Sequences were analyzed with Seqman II 
Software (DNASTAR I Lasergene 7.0; DNASTAR, Madison, 
WI, USA). PCR amplification and Sanger sequencing primers 
to confirm the MVK (NM_000431) mutations (c.1129G>A; 
p.V377I) and (c.404C>T; p.S135L) were: MVK5 forward, 
5'-GTTGAGAAAACTGGACCAGATGC-3' and MVK5 
reverse, 5'-CTCAGCTTCCTCATGTTAAAATG-3'; and 
MVK11 forward, 5'-GGCTTTTGCCTTGAATATGATGA-3' 
and MVK11 reverse, 5'-GGGCCTCTCCAGCAGTGTC-3'. 
PCR amplification and Sanger sequencing primers to confirm 
the RAB40AL (NM_001031834) known dinucleotide missense 
changes c.A176G and c.C177A, leading to p.D59G were: 
RAB40AL forward, 5'-CCTCTGCGCACAACCTTGC-3' and 
RAB40AL reverse, 5'- CTGGAGCGATTCCAGCTTG-3'. 
Primers were obtained from Integrated DNA Technologies 
(Coralville, IA, USA). PCR amplification cycle: Initial dena-
turation (95˚C for 1 sec), 30 cycles of denaturation (95˚C for 
10 sec), annealing (60˚C for 10 sec) and elongation (72˚C 
for 5 sec), followed by a final elongation (72˚C for 30 sec). 
Sequence reaction cycle: Initial denaturation (96˚C for 3 sec), 
26 cycles of denaturation (96˚C for 30 sec), annealing (53˚C for 
15 sec) and elongation (60˚C for 4 sec).
RAB40AL inactivation analysis. 300 ng genomic DNA of the 
patient was digested with 40 U HpaII methylation-sensitive 
restriction enzyme and 20 U RsaI methylation-insensitive 
restriction enzyme (New England Biolabs, Ipswich, MA, 
USA) in a total volume of 20 µl for 24 h at 37˚C. After diges-
tion, the mixtures were incubated at 95˚C for 10 min. 50 ng 
digested and undigested DNA were amplified with RAB40AL 
forward and reverse primers as previously described to verify 
the inactivation of the gene.
X-chromosome inactivation (XCI) analysis via androgen 
receptor. 300 ng genomic DNA of the patient's mother was 
digested as described above and incubated at 95˚C for 10 min. 
50 ng of digested and undigested DNA was amplified with 
primers 5'-GCTGTGAAGGTTGCTGTTCCTCAT-3' and 
5'-56-FAM/TCCAGAATCTGTTCCAGAGCGTGC-3' 
according to the protocol of a previous study (9) for ampli-
fication of a region of the human androgen receptor (HAR) 
gene, localized on Xq12 and characterized by a polymorphic 
number of CAG repeats. Since this fragment has two HpaII 
restriction enzyme sites, only methylated DNA was amplified.
XCI analysis via the polymorphic marker DXS1214. 300 ng 
genomic DNA of the patient's mother was digested as described 
above and incubated at 95˚C for 10 min. 50 ng digested and 
undigested DNA was amplified with specific DXS1214-labeled 
primers.
The labeled PCR products were denatured and run on 
the automated sequencer (ABI 3730XL Platform; Applied 
Biosystems) using the POP7 polymer and the ROX size 
standard as size markers (Invitrogen Life Technologies, Inc.). 
GeneMapper software (v. 4.0; Applied Biosystems) was used 
for fragment analysis.
Biochemical analysis. Urinary mevalonic acid was determined 
by means of gas chromatography/mass spectrometry. Spectra 
were obtained using a Hewlett Packard gas chromatograph 
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6890 series equipped with a Hewlett Packard 5973 quadrupole 
operating in electron‑impact mode at 70 eV (Hewlett Packard, 
Palo Alto, CA, USA) (10).
Results and Discussion
WES revealed two missense mutations of the MVK gene (hetero-
zygous): NM_000431, c.1129G>A; p.V377I (rs28934897); and 
NM-000431, c.404C>T; p.S135L (rs104895297). In addition, 
the known dinucleotide missense mutations of the RAB40AL 
(NM_001031834) gene were detected: c. A176G (rs145606134) 
and c. C177A (rs138133927), leading to p.D59G. Sanger 
sequencing analysis confirmed all mutations. No mutations 
were detected in genes associated with diabetes insipidus.
The MVK gene encodes mevalonate kinase, the third 
enzyme on the pathway leading to the synthesis of choles-
terol from acetyl-CoA (11). Mutations of the MVK gene 
cause a recessive inherited disease called mevalonate 
kinase deficiency (MKD), which manifests as a clinical 
and biochemical continuum with mevalonic aciduria at 
the most severe end [MA; online mendelian of inheritance 
in man (OMIM) #610377] and hyper immunoglobulin D 
and periodic fever syndrome at the mildest end (HIDS; 
OMIM #260920) (12).
The D59G variant of RAB40AL has already been 
reported as causative of the Martin-Probst syndrome (MPS; 
OMIM #300519), a recessive X‑linked disease characterized 
by congenital sensorineural hearing loss, mental retardation, 
short stature, congenital umbilical hernia, facial dysmorphism, 
abnormal teeth, widely spaced nipples and abnormal dermato-
glyphics (13,14). In the present study, a multidisciplinary team 
discussed the relevance of the genetic results in order to compare 
the patient's clinical features with those pertaining to MKD and 
MPS, based on clinical, genetic and functional evaluations.
The diagnosis of MKD was supported not only by the fact 
that the two mutations detected have a well known role in the 
Table I. Main symptoms for MP syndrome and MK deficiency compared with the symptoms of patient of the present study.
 
Feature MP syndrome MK deficiency Patient
 
Growth Short stature From failure to thrivea to normal;  Normal
  hyper immunoglobulin D; 
  periodic fever syndrome
Head Microcephaly Microcephalya Normal
Ears Hearing loss Normal Normal
Eye Normal Central cataractsa Normal
Dysmorphisms Low-set ears Triangular facea,  Normal
 Telecanthus Hypoplastic alae nasia
 Hypertelorism
 Epicanthal folds  
 Broad nasal root
 Broad mouth
 Full lower lip
 Abnormal teeth
Genitourinary Bifid scrotum Normal Normal
 Small phallus
 Cryptorchidism  
 Hypoplastic kidneys
 Renal insufficiency
Skin Telangiectasias Skin rashes Skin rashes
Central nervous system Mental retardation,  Psychomotor retardationa,  Neurogenic diabetes
  mild to severe Cerebella ataxiaa insipidus
Osteoarticular system Normal Arthralgia/arthritis Normal
Endocrine features Hypothyroidism Normal Normal
Hematology Pancytopenia Anemia Mild anemia
Lymphoid organs Leukopenia Lymphadenopathy,  Lymphadenopathy, 
  hepato-splenomegaly hepato-splenomegaly
Molecular Basis RAB40AL MVK MVK V377I/S135L
   RAB40AL D59G
 
aPhenotypic features of mevalonic aciduria. MV, mevalonate kinase; MP, Martin Probst.
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disease, but also by a biochemical analysis that demonstrated 
the accumulation of mevalonic acid [5,496 µg/ml; the normal 
range of mevalonic acid levels is 34-323 µg/ml (internal labora-
tory reference)] in urine during febrile crisis, as a proof of MK 
enzyme deficiency (10).
In the case of the present study, the diagnosis of MKD 
adequately explained the proband's condition, apart from the 
presence of neurogenic diabetes insipidus (Table I). 
In fact, most of the clinical features of the patient are charac-
teristics of MKD, although a large number of MKD-associated 
symptoms were not present in the patient. In particular, 
diabetes insipidus, which was one of the main complaints of 
the patient, is not characteristic of MKD. By contrast, no sign 
or symptom of MPS was present in the patient. Since MPS is 
described as an X-recessive disease with complete penetrance, 
it was unexpected that the patient had not developed any of the 
severe impairments, which are typical of the disease. It was 
thus hypothesized that either the defect in MK has a protec-
tive effect against the development of MPS or that the variant 
detected in RAB40AL is not the actual cause of MPS. Of note, 
the variant identified in RAB40AL was predicted to affect 
protein farnesylation; however, MKD is also associated with 
an abnormal pattern of protein prenylation due to a shortage 
of mevalonate-derived isoprenoids (15,16). However, consid-
ering that the two defects can reduce protein farnesylation, the 
combined effect of the two defects would have been expected 
to be even more severe. On the contrary, the National Heart, 
Lung and Blood Institute-exome sequencing project (ESP)6500 
database (http://evs.gs.washington.edu/EVS/) lists two healthy 
males carrying the D59G variant of RAB40AL, suggesting that 
it represents an irrelevant albeit rare polymorphism. In addition, 
recent studies described the same RAB40AL variant in a patient 
with a distinctly different phenotype from that reported in MPS 
patients (17,18).
To ascertain the possibility that RAB40AL is not the caus-
ative gene of MPS, the present study exploited the opportunity 
of studying the mother of the patient, who is a heterozygous 
carrier of the same gene variant. Bedoyan et al (13) demon-
strated that, while males affected by MPS develop progressive 
loss of white blood cells, female carriers have a normal leuko-
cyte count and display a skewed XCI in peripheral blood cells. 
The present study then attempted to analyze the inactivation 
profile of RAB40AL by amplifying the gene after digestion with 
a methylation-sensitive enzyme (19,20). However, it was not 
possible to amplify RAB40AL after HpaII digestion, suggesting 
that this gene escapes inactivation (Fig. 1A). In order to verify 
the hypothesis of a skewed XCI, the present study then used 
polymorphic X‑chromosome markers known to undergo meth-
ylation and inactivation. As the most widely used androgen 
receptor humara locus was uninformative in the patient's family, 
Figure 1. (A) Humara PCR results from digested genomic DNA (HpaII) and uncut DNA. The RAB40AL PCR product could only be amplified from undigested 
DNA. (B) Analysis of the DXS1214 polymorphic marker in genomic DNA digested with HpaII and in DNA digested with RsaI. The graphs suggest a balanced 
X inactivation. PCR, polymerase chain reaction.
  A
  B
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the polymorphic marker DXS1214 was then analyzed. After 
digestion with HpaII, which is selective for active unmethylated 
DNA, the two DXS1214 polymorphic alleles remained present 
to similar extents, confirming a balanced XCI (Fig. 1B). These 
results suggested that the pattern of skewed XCI in the family 
examined by Bedoyan et al (13) is not due to the D59G variant 
in RAB40AL, but to another unidentified X‑chromosome gene 
mutation. In conclusion, these results suggested that mutations 
of RAB40AL are not the cause of MPS.
The case of the present study confirmed the potential of 
the NGS technique to identify pathogenic and causative muta-
tions, but also highlighted the crucial role of an expert team 
performing the critical revision of all detected WES variants. 
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